34th PAGE Meeting

Dubrovnik - Croatia
2-5 June, 2026

View abstracts

Home / 2026 – Dubrovnik – Croatia / Abstracts

← Back to filters

Abstracts (50)

I-013Avuyonke Balfour

FOUR-SNP NAT2 GENOTYPING OUTPERFORMS TAG-SNP AND MIXTURE MODELS FOR HIGH-DOSE ISONIAZID PK

Wed, Jun 3, 2026 10:30AM–12:00PM

I-014Milena M. Boczar

PILOT STUDY AIMING TO QUANTIFY VIABLE BUT NON- OR SLOWLY REPLICATING MYCOBACTERIUM TUBERCULOSIS BACTERIA

Wed, Jun 3, 2026 10:30AM–12:00PM

I-015Harel Dahari

Modeling the Effect of Long-Acting Injectables of DAA Therapy to Reach Hepatitis C Elimination among People Who Inject Drugs

Wed, Jun 3, 2026 10:30AM–12:00PM

I-016Rasmus Henninger

Semi-mechanistic translational PK/PD modelling to support human dose selection of DNDI-6174 in cutaneous leishmaniasis

Wed, Jun 3, 2026 10:30AM–12:00PM

I-017Albin Leding

Translational prediction of pharmacologically active metabolite contribution to the relative efficacy of TBAJ-587 for early clinical development

Wed, Jun 3, 2026 10:30AM–12:00PM

I-018Leichi Liu

POPULATION PHARMACOKINETICS OF BICTEGRAVIR CO-ADMINISTERED WITH RIFAMPICIN IN ADULTS WITH HIV AND TUBERCULOSIS

Wed, Jun 3, 2026 10:30AM–12:00PM

I-019Wen Yao Mak

INTER-LABORATORY EFFECTS ON PK/PD RELATIONSHIPS IN THE STANDARDIZED COMBINE PNEUMONIA MODEL

Wed, Jun 3, 2026 10:30AM–12:00PM

I-020Grigory Nesvijevski

MINIMAL-PBPK URINARY MODEL AND FRAMEWORK FOR INVESTIGATION OF NITROFURANTOIN, CIPROFLOXACIN AND FOSFOMYCIN EFFECT ON ESCHERICHIA COLI IN MICROFLUIDIC-BASED HOLLOW FIBER INFECTION MODEL

Wed, Jun 3, 2026 10:30AM–12:00PM

I-021Tamara Ray

PYRAZINAMIDE POPULATION PHARMACOKINETICS IN ADULTS WITH DRUG-RESISTANT TUBERCULOSIS: THE ROLE OF ALLOMETRIC SCALING

Wed, Jun 3, 2026 10:30AM–12:00PM

I-022Anh Quan Truong

A PROOF-OF-CONCEPT MECHANISTIC, SYSTEM-BASED FRAMEWORK INTEGRATING HUMAN CYTOKINES, GRANULOPOIESIS, ANTIMICROBIAL PHARMACOKINETICS, AND IN VITRO TIME-KILL EXPERIMENTS FOR HOST – PATHOGEN – ANTIMICROBIAL INTERACTIONS

Wed, Jun 3, 2026 10:30AM–12:00PM

I-023Roland van Rensburg

POPULATION PHARMACOKINETIC MODEL OF EXTENDED-RELEASE METFORMIN IN OBESE SOUTH AFRICAN WOMEN WITH HIV RECEIVING DOLUTEGRAVIR

Wed, Jun 3, 2026 10:30AM–12:00PM

I-024Suzanne A.M. Wenker

(Val)ganciclovir against cytomegalovirus: Are we currently dosing too low?

Wed, Jun 3, 2026 10:30AM–12:00PM

II-012Marie Alexandre

Joint mechanistic modeling of viral and antibody responses to vaccines in Non-Human Primates to quantify SARS-CoV-2 mechanistic correlate of protection.

Wed, Jun 3, 2026 3:20PM–4:50PM

II-013Maxime Beaulieu

The analysis of a large dataset of PCR-test results in the community reveals the impact of age, variants and vaccination status on SARS-CoV-2 viral dynamics

Wed, Jun 3, 2026 3:20PM–4:50PM

II-014Clémence Boivin-champeaux

A multi-compartment QSP model of hepatitis B infection linking viral life cycle and immune regulation to support model-informed therapy evaluation

Wed, Jun 3, 2026 3:20PM–4:50PM

II-015Ibrahim El-haffaf

Exploring the impact of extracorporeal membrane oxygenation (ECMO) therapy on piperacillin pharmacokinetics: do general intensive care unit models perform similarly to ECMO models?

Wed, Jun 3, 2026 3:20PM–4:50PM

II-016Jaegu Kang

Population Pharmacokinetic Modeling of Vancomycin in Ventricular Assist Device Implanted Patients: Exploration for Role of Hemodynamic Parameters

Wed, Jun 3, 2026 3:20PM–4:50PM

II-017Jessica Lee

TRANSLATIONAL PKPD MODELLING FRAMEWORK TO SUPPORT PRIORITISATION OF NOVEL TUBERCULOSIS REGIMENS WITHIN THE PARADIGM4TB PLATFORM.

Wed, Jun 3, 2026 3:20PM–4:50PM

II-018Rentia Lourens

POPULATION PHARMACOKINETICS AND PHARMACOGENOMICS OF ETHAMBUTOL IN AN AFRICAN COHORT WITH DRUG RESISTANT PULMONARY TUBERCULOSIS

Wed, Jun 3, 2026 3:20PM–4:50PM

II-019Andrés Mazariegos Herrera

An individual patient data meta-analysis of miltefosine pharmacokinetics across clinical forms of leishmaniasis

Wed, Jun 3, 2026 3:20PM–4:50PM

II-020Thi Minh Nguyet Nguyen

Modelling pharmacokinetic-pharmacodynamic of PBTZ169 in glycerol and cholesterol using CFU and MPN as biomarkers

Wed, Jun 3, 2026 3:20PM–4:50PM

II-021Michael Jacques Rossouw

EFFECT OF METFORMIN ON THE PHARMACOKINETICS OF RIFAMPICIN, ISONIAZID, AND PYRAZINAMIDE IN ADULTS WITH TB AND HIV

Wed, Jun 3, 2026 3:20PM–4:50PM

II-022Ruben van de Venter

Population Pharmacokinetics of Dolutegravir with Daily Rifapentine for HIV-associated Tuberculosis

Wed, Jun 3, 2026 3:20PM–4:50PM

II-023Alberto Vegas Rodriguez

Development of an In-Silico Platform to Explore HIV Incidence Across Different Regions and Its Application to PrEP Clinical Trials for Treatment Design and Optimization

Wed, Jun 3, 2026 3:20PM–4:50PM

II-024Tan Zhang

Population pharmacokinetic–based probability of target attainment analysis of cefepime/nacubactam and aztreonam/nacubactam for carbapenem-resistant enterobacterales infections

Wed, Jun 3, 2026 3:20PM–4:50PM

III-012Malin Andersson

GLOBAL VARIANCE-BASED SENSITIVITY ANALYSIS OF A PHARMACODYNAMIC MODEL FOR PIPERACILLIN/TAZOBACTAM TOWARDS OPTIMISED DOSING STRATEGIES

Thu, Jun 4, 2026 9:50AM–11:20AM

III-013Thomas Bénéteau

ON THE USE OF TECOVIRIMAT FOR MPXV INFECTIONS: WHY DO WE NOT SEE SHORTENED TIMES TO VIRAL CLEARANCE IN TREATED PATIENTS?

Thu, Jun 4, 2026 9:50AM–11:20AM

III-014Jordan Brooks

Model-Informed Precision Dosing of Cefepime: A Simulation Study Evaluating Target Attainment and Neurotoxicity Risk

Thu, Jun 4, 2026 9:50AM–11:20AM

III-015Asina Gijasi

PRECLINICAL-TO-CLINICAL PREDICTIONS OF PHASE 2B CLINICAL TRIAL EFFICACY IN TUBERCULOSIS THROUGH BACK-TRANSLATIONAL MODELING OF RIFAPENTINE-CONTAINING REGIMENS

Thu, Jun 4, 2026 9:50AM–11:20AM

III-016Evangelos Karakitsios

A translational framework for predicting early bactericidal activity of bedaquiline and pretomanid using in vitro time-kill assays

Thu, Jun 4, 2026 9:50AM–11:20AM

III-017Xuanlin Liu

LATE TREATMENT INITIATION LEADS TO REDUCED ANTIVIRAL POTENCY OF NIRMATRELVIR AND GS-441524 AGAINST IN VITRO SARS-COV-2 INFECTION

Thu, Jun 4, 2026 9:50AM–11:20AM

III-018Chen Ma

Host Immunity as a Bidirectional Regulator of Phage Therapy: A Mechanism-Based PKPD Modeling Approach

Thu, Jun 4, 2026 9:50AM–11:20AM

III-019Yersultan Mirasbekov

Population pharmacokinetic modelling of plasma and target-site metronidazole: Reduced target-site exposure suggests underdosing in obese patients

Thu, Jun 4, 2026 9:50AM–11:20AM

III-020Emmanuel Niyigena

Population Pharmacokinetic Modelling of Plasma and Intracellular Bictegravir in People Living with HIV

Thu, Jun 4, 2026 9:50AM–11:20AM

III-021Sharon Sawe

POPULATION PHARMACOKINETICS OF DELAMANID AND ITS MAIN METABOLITE DM-6705 IN BREASTMILK IN PATIENTS TREATED FOR RIFAMPICIN-RESISTANT TUBERCULOSIS

Thu, Jun 4, 2026 9:50AM–11:20AM

III-022Isabella Van Der Feltz

Pharmacokinetic and pharmacodynamics of BTZ-043 in patients with pulmonary tuberculosis

Thu, Jun 4, 2026 9:50AM–11:20AM

III-023Eva Wehrhahn

Time-varying covariates to enhance mechanistic understanding of antibiotic-induced bacterial morphology changes

Thu, Jun 4, 2026 9:50AM–11:20AM

III-024Thijs Jan Zweers

POPULATION PHARMACOKINETICS, ANTIDRUG ANTIBODIES AND EXPOSURE–RESPONSE OF LOTIVIBART (LVB, VH3810109, N6LS) IN VIROLOGICALLY SUPPRESSED ADULTS LIVING WITH HIV FROM THE PHASE 2B EMBRACE STUDY

Thu, Jun 4, 2026 9:50AM–11:20AM

IV-012Guiva Annane

ASSESSMENT OF PIPERACILLIN–TAZOBACTAM VARIABILITY IN OBESITY THROUGH POPULATION PHARMACOKINETIC MODELING

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-013Daniele Boaretti

A lesion-centric extension of a minimal PBPK model to predict anti-tuberculosis drug target attainment in rabbits

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-014Vasileios Chronopoulos

A Translational Multiscale Model Integrating Immune Response, Bacterial Dynamics, and Lung PBPK to Predict Tuberculosis Treatment Response

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-015Sylvain Goutelle

A pharmacometric model of the in vitro co-dynamics of Staphylococcus aureus and three phage candidates

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-016Allan Kengo

Drug interaction between pyrazinamide and standard- and high-dose rifampicin

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-017Chenyao Liu

Population pharmacokinetics–driven optimization of CFU-reduction study design for boosted ethionamide combinations in mice

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-018Ruvarashe Joylyne Madzime

Linezolid Pharmacokinetics in Adults with Rifampicin-Resistant TB: Impact of Pregnancy and Lactation

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-019Laura Mulas

Quantifying host and vaccination determinants of viral dynamics in respiratory infections using community-based PCR data

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-020Italo Poggesi

Population Pharmacokinetic Model of Tebipenem (TBP) in Blood and Plasma after Oral Administration of Tebipenem Pivoxil (TBP-PI) in Adult Participants.

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-021Nichada Seriniyom

PHARMACOKINETICS OF HPMZ TREATMENT IN CYNOMOLGUS MACAQUES: RECOMMENDATIONS FOR A PROSPECTIVE EFFICACY STUDY WITH ANTITUBERCULAR DRUGS.

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-022Bart van Lieshout

THE TRANSLATIONAL ZEBRAFISH LARVAE FRAMEWORK ACCURATELY PREDICTS BEDAQUILINE’S CLINICAL EARLY BACTERICIDAL ACTIVITY AGAINST TUBERCULOSIS

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-023Haini Wen

MODEL-INFORMED DOSING STRATEGIES FOR INHALED AMINOGLYCOSIDES IN NOSOCOMIAL PNEUMONIA

Thu, Jun 4, 2026 1:40PM–3:10PM